©The Author(s) 2025.
World J Gastrointest Pharmacol Ther. Jun 5, 2025; 16(2): 105801
Published online Jun 5, 2025. doi: 10.4292/wjgpt.v16.i2.105801
Published online Jun 5, 2025. doi: 10.4292/wjgpt.v16.i2.105801
Table 1 Patient characteristics, n (%)
| Number of patients | n = 80 |
| Sex | |
| Male | 29 (36.3) |
| Female | 51 (63.8) |
| Age | 66.156 ± 13.961 |
| Bristol Stool Form Scale | |
| Type 1 | 18 (22.5) |
| Type 2 | 32 (40) |
| Type 3 | 30 (37.5) |
| Type 4 | 0 (0) |
| Type 5 | 0 (0) |
| Type 6 | 0 (0) |
| Type 7 | 0 (0) |
| 1-week frequency of bowel movements before elobixibat administration | 2.013 ± 0.639 |
| Number of drugs to relieve constipation before elobixibat administration | |
| 0 | 28 (35) |
| 1 magnesium oxide tablet | 32 (40) |
| 2 magnesium oxide tablets + sennoside | 20 (25) |
| Comorbidity | |
| Hypertension | 38 (47.5) |
| Hyperlipidemia | 36 (45) |
| Diabetes mellitus | 35 (43.8) |
| Cerebrovascular disease | 16 (20) |
| Chronic respiratory disease | 13 (16.3) |
| Cardiac disease | 22 (27.5) |
| Chronic hepatic disease | 18 (22.5) |
| Chronic renal disease | 10 (12.5) |
| Malignant disease | 6 (7.5) |
| Post cholecystectomy | 18 (22.5) |
- Citation: Sakai Y, Tsuyuguchi T, Kumagai J, Ohyama H, Kaiho T, Ohtsuka M, Kato N. Efficacy of elobixibat for elderly patients with chronic constipation in a clinic. World J Gastrointest Pharmacol Ther 2025; 16(2): 105801
- URL: https://www.wjgnet.com/2150-5349/full/v16/i2/105801.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v16.i2.105801